Purdue University researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the Food and Drug Administration to treat life-threatening...

Medicines Development for Global Health (MDGH) and the World Health Organisation Special Programme for Research and Training in Tropical Diseases (TDR) announced today that the United States (U.S.)...

In a follow-up to recommendations published in April 2017, the Centers for Disease Control and Prevention (CDC) issued updated recommendations on management and reporting of Shigella infections that...

A new study has found that the majority of residents in a rural village of Vietnam harbored multi-drug-resistant (MDR), colistin-resistant E. coli bacteria. Colistin is typically used as a last-resort...

In a viral haemorrhagic disease where up to 40% of people developing it die, it is remarkable that doctors still do not agree whether the only recognized treatment, an antiviral drug called ribavirin,...

The U.S. Food and Drug Administration today approved Palynziq (pegvaliase-pqpz) for adults with arare and serious genetic disease known as phenylketonuria (PKU). Patients with PKU are born with an...

A first-in-human trial evaluating an experimental treatment for Ebola virus disease has begun at the National Institutes of Health Clinical Center in Bethesda, Maryland. The Phase 1 clinical trial is...

Results RNA, LLC of Orem, UT was issued a warning letter from the Food and Drug Administration (FDA) last month over a number of unapproved/misbranded new drugs sold, including one for Lyme disease, where serious...

A recent CDC MMWR report shows that providers treated 81% of patients diagnosed with gonorrhea using CDC’s recommended dual therapy. While encouraging, nearly 1 in 5 patients were treated with a different...

New Jersey based biotechnology company, SCYNEXIS, Inc. announced this week that the U.S. Food and Drug Administration(FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track...